TY - JOUR
T1 - Incidence and risk factors of early onset neonatal AKI
AU - on behalf of the Neonatal Kidney Collaborative
AU - Charlton, Jennifer R.
AU - Boohaker, Louis
AU - Askenazi, David
AU - Brophy, Patrick D.
AU - D’Angio, Carl
AU - Fuloria, Mamta
AU - Gien, Jason
AU - Griffin, Russell
AU - Hingorani, Sangeeta
AU - Ingraham, Susan
AU - Mian, Ayesa
AU - Ohls, Robin K.
AU - Rastogi, Shantanu
AU - Rhee, Christopher J.
AU - Revenis, Mary
AU - Sarkar, Subrata
AU - Smith, Alexandra
AU - Starr, Michelle
AU - Kent, Alison L.
AU - Ambalavanan, Namasivayam
AU - Selewski, David T.
AU - Abitbol, Carolyn L.
AU - DeFreitas, Marissa
AU - Guillet, Ronnie
AU - Mhanna, Maroun J.
AU - Raina, Rupesh
AU - Kumar, Deepak
AU - Arikan, Ayse Akcan
AU - Goldstein, Stuart L.
AU - Nathan, Amy T.
AU - Kupferman, Juan C.
AU - Bhutada, Alok
AU - Bonachea, Elizabeth
AU - Mahan, John
AU - Nada, Arwa
AU - Jetton, Jennifer
AU - Colaizy, Tarah T.
AU - Klein, Jonathan M.
AU - Cole, F. Sessions
AU - Davis, T. Keefe
AU - Dower, Joshua
AU - Milner, Lawrence
AU - Reidy, Kimberly
AU - Kaskel, Frederick J.
AU - Gist, Katja M.
AU - Hanna, Mina H.
AU - Wong, Craig S.
AU - Joseph, Catherine
AU - DuPont, Tara
AU - Staples, Amy
N1 - Funding Information:
The authors would like to thank the outstanding work of the following clinical research personnel and colleagues for their involvement in Assessment of Worldwide AKI Epidemiology in Neonates (AWAKEN): Ariana Aimani, Ana Palijan, Michael Pizzi- Montreal Children’s Hospital, McGill University Health Centre, Montreal, Quebec, Canada; Julia Wrona-University of Colorado, Children’s Hospital Colorado, Aurora, Colorado;Melissa Bowman- University of Rochester, Rochester, NewYork; Teresa Cano,Marta G. Galarza, Wendy Glaberson, Denisse Cristina Pareja Valarezo-Holtz Children’s Hospital, University of Miami, Miami, Florida; Sarah Cashman, Madeleine Stead-University of Iowa Children’s Hospital, Iowa City, Iowa; Jonathan Davis, Julie Nicoletta- Floating Hospital for Children at Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts; Alanna DeMello-British Columbia Children’s Hospital, Vancouver, British Columbia, Canada; Lynn Dill, Emma Perez-Costas- University of Alabama at Birmingham, Birmingham, Alabama; Ellen Guthrie-MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio; Nicholas L. Harris, Susan M. Hieber-C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor, Michigan; Katherine Huang, Rosa Waters-University of Virginia Children’sHospital, Charlottesville, Virginia; Judd Jacobs, Tara Terrell-Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; Nilima Jawale-Maimonides Medical Center, Brooklyn, New York; Emily Kane-Australian National University, Canberra, Australia; Patricia Mele-Stony Brook Children’s Hospital, Stony Brook, New York; Charity Njoku, Tennille Paulsen, Sadia Zubair-Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas; Emily Pao-University of Washington, Seattle Children’s Hospital, Seattle, Washington; Becky Selman, Michele Spear-University of New Mexico Health Sciences Center, Albuquerque, New Mexico; Melissa Vega-The Children’s Hospital at Montefiore, Bronx, New York; and Leslie Walther- Washington University, St. Louis, Missouri. Cincinnati Children’s Hospital Center for Acute Care Nephrology provided funding to create andmaintain the AWAKEN Medidata Rave electronic database. The Pediatric and Infant Center for Acute Nephrology (PICAN)provided support for web meetings, for theNeonatal Kidney Collaborative steering committee annual meeting at the University of Alabamaat Birmingham(UAB), as well as support for someof theAWAKENinvestigators atUAB(D.A.,L.B., andR.G.).PICANispart of the Department of Pediatrics at UAB, and is funded by Children’s of Alabama Hospital, the Department of Pediatrics, UAB School of Medicine, andUAB’sCenter for Clinical andTranslational Sciences (National Institutes of Health [NIH] grant UL1TR001417). The AWAKEN study was supported at the University of New Mexico by the Clinical and Translational Science Center (NIH grant UL1TR001449). We provide here an additional list of other author’s commitments andfundingsources that arenotdirectlyrelatedto this study: J.R.C. is a co-owner of Sindri Technologies, LLC. She receives funding from the NIHNational InstitutesofDiabetesandDigestiveandKidneyDiseases (NIDDK; R01DK110622, R01DK111861, P50DK096373). D.A. serves on the speaker board for Baxter and the AKI Foundation (Cincinnati, OH); he also receives grant funding for studies not related to this manuscript from Octapharma AG (Switzerland), Otsuka Pharmaceuticals (MD), and the NIH NIDDK (R01 DK103608). J.R.C. andA.L.K. contributed to the conceptualization anddesign of the study, collecteddata, aidedthedata analysis, anddraftedthe initial manuscript. L.B. and R.G. completed the data analysis and interpretation, and contributed to the drafting and revising of the manuscript. D.A. contributed to the conceptualization and design of the study, aided in data analysis, and contributed to the revising of the manuscript for critically important intellectual content. P.D.B., C.D., M.F., J.G., S.H., S.I., A.M., R.K.O., S.R.,C.J.R.,M.R., S.S.,A.S., andM.S. contributedtothe studydesign, collecting or supervising the collection of data, and revising the manuscript for critically important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Funding Information:
We provide here an additional list of other author’s commitments andfundingsourcesthatarenotdirectlyrelatedtothisstudy:J.R.C.isa co-owner of Sindri Technologies, LLC. She receives funding from the NIHNationalInstitutesofDiabetesandDigestiveandKidneyDiseases (NIDDK; R01DK110622, R01DK111861, P50DK096373). D.A. serves on the speaker board for Baxter and the AKI Foundation (Cincinnati, OH); he also receives grant funding for studies not related to this manuscript from Octapharma AG (Switzerland), Otsuka Pharmaceuticals (MD), and the NIH NIDDK (R01 DK103608).
Funding Information:
Cincinnati Children’s Hospital Center for Acute Care Nephrology provided funding to create and maintain the AWAKEN Medidata Rave electronic database. The Pediatric and Infant Center for Acute Nephrology (PICAN) provided support for web meetings, for the Neonatal Kidney Collaborative steering committee annual meeting at the University of Alabama at Birmingham (UAB), as well as support for some of the AWAKEN investigators at UAB (D.A., L.B., and R.G.). PICAN is part of the Department of Pediatrics at UAB, and is funded by Children’s of Alabama Hospital, the Department of Pediatrics, UAB School of Medicine, and UAB’s Center for Clinical and Translational Sciences (National Institutes of Health [NIH] grant UL1TR001417). The AWAKEN study was supported at the University of New Mexico by the Clinical and Translational Science Center (NIH grant UL1TR001449).
Publisher Copyright:
© 2019 by the American Society of Nephrology.
PY - 2019/2/7
Y1 - 2019/2/7
N2 - Background and objectives Neonatal AKI is associated with poor short- and long-term outcomes. The objective of this study was to describe the risk factors and outcomes of neonatal AKI in the first postnatal week. Design, setting, participants, & measurements The international retrospective observational cohort study, Assessment of World wide AKI Epidemiology in Neonates (AWAKEN), included neonates admitted to a neonatal intensive care unit who received at least 48 hours of intravenous fluids. Early AKI was defined by an increase in serumcreatinine>0.3mg/dl or urine output<1ml/kg per hour on postnatal days 2-7, the neonatal modification of Kidney Disease: Improving Global Outcomes criteria.We assessed risk factors forAKI and associations of AKI with death and duration of hospitalization. ResultsTwenty-onepercent (449of 2110) experienced early AKI.Early AKI was associated with higher riskof death (adjusted odds ratio, 2.8; 95% confidence interval, 1.7 to 4.7) and longer duration of hospitalization (parameter estimate: 7.3 days 95% confidence interval, 4.7 to 10.0), adjusting for neonatal and maternal factors along with medication exposures. Factors associated with a higher risk of AKI included: outborn delivery; resuscitation with epinephrine; admission diagnosis of hyperbilirubinemia, inborn errors of metabolism, or surgical need; frequent kidney function surveillance; and admission to a children’s hospital. Those factors that were associated with a lower risk includedmultiplegestations,cesarean section,andexposuresto antimicrobials,methylxanthines, diuretics,and vasopressors. Risk factors varied by gestational age strata. Conclusions AKI in the first postnatal week is common and associated with death and longer duration of hospitalization. The AWAKEN study demonstrates a number of specific risk factors that should serve as “red flags” for clinicians at the initiation of the neonatal intensive care unit course.
AB - Background and objectives Neonatal AKI is associated with poor short- and long-term outcomes. The objective of this study was to describe the risk factors and outcomes of neonatal AKI in the first postnatal week. Design, setting, participants, & measurements The international retrospective observational cohort study, Assessment of World wide AKI Epidemiology in Neonates (AWAKEN), included neonates admitted to a neonatal intensive care unit who received at least 48 hours of intravenous fluids. Early AKI was defined by an increase in serumcreatinine>0.3mg/dl or urine output<1ml/kg per hour on postnatal days 2-7, the neonatal modification of Kidney Disease: Improving Global Outcomes criteria.We assessed risk factors forAKI and associations of AKI with death and duration of hospitalization. ResultsTwenty-onepercent (449of 2110) experienced early AKI.Early AKI was associated with higher riskof death (adjusted odds ratio, 2.8; 95% confidence interval, 1.7 to 4.7) and longer duration of hospitalization (parameter estimate: 7.3 days 95% confidence interval, 4.7 to 10.0), adjusting for neonatal and maternal factors along with medication exposures. Factors associated with a higher risk of AKI included: outborn delivery; resuscitation with epinephrine; admission diagnosis of hyperbilirubinemia, inborn errors of metabolism, or surgical need; frequent kidney function surveillance; and admission to a children’s hospital. Those factors that were associated with a lower risk includedmultiplegestations,cesarean section,andexposuresto antimicrobials,methylxanthines, diuretics,and vasopressors. Risk factors varied by gestational age strata. Conclusions AKI in the first postnatal week is common and associated with death and longer duration of hospitalization. The AWAKEN study demonstrates a number of specific risk factors that should serve as “red flags” for clinicians at the initiation of the neonatal intensive care unit course.
UR - http://www.scopus.com/inward/record.url?scp=85065245443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065245443&partnerID=8YFLogxK
U2 - 10.2215/CJN.03670318
DO - 10.2215/CJN.03670318
M3 - Article
C2 - 31738181
AN - SCOPUS:85065245443
SN - 1555-9041
VL - 14
SP - 184
EP - 195
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 2
ER -